NKT Brings In $4M

Erin Kutz8/25/10

Waltham, MA-based NKT Therapeutics, a developer of drugs targeting lesser-known immune cells potentially linked to a number of major illnesses, raised $4 million in an equity round from three unnamed investors, according to an SEC filing. Last year, the company raised an $8 million Series A round led by SV Life Sciences and MedImmune Ventures. Ryan wrote about the company’s plans to develop drugs that stimulate white blood cells called natural killer T cells as part of a broader immune response to conditions like asthma and cancer.

Erin Kutz is an Associate Editor for Xconomy. You can reach her by e-mail at ekutz@xconomy.com or by phone at (617) 252-0700, or follow her on Twitter at @erkutz.